Colon adenoma prevention with celecoxib, a non-steroidal anti-inflammatory drug (NSAID), is effective and can be safe for patients without underlying cardiovascular risk factors, according to five-year data of a randomized phase III trial. "There has been a significant amount of negative press about Cox-2 inhibitors including celecoxib, and clearly these drugs are risky for some patients. However, our study also shows that for patients without major cardiovascular risk factors, celecoxib at low doses protects against high-risk lesions that can lead to colon cancer," said an associate professor of surgery at the Brigham and Women's Hospital.
More...